3rd Jun 2025 14:02
(Alliance News) - Solvonis Therapeutics PLC on Tuesday announced the appointment of neuroscience professor David Nutt as its chief scientific officer, with immediate effect.
Nutt has previously served as senior scientific advisor at the London-based biotechnology firm since July last year. Also, he leads the Neuropsychopharmacology Unit at Imperial College London's Division of Brain Sciences.
Solvonis, which focuses on developing therapeutics for mental health and substance use disorders, said Nutt "is one of the world's foremost authorities in brain science and psychiatric medicine".
It added that his work "has played a pivotal role in translating neuroscience into effective clinical interventions" and "has significantly advanced the understanding and treatment of central nervous system ["CNS"] disorders".
"David is one of the most accomplished neuroscientists of his generation," commented Chief Executive Officer Anthony Tennyson. "His contributions to our understanding of brain chemistry and psychiatric illness are unmatched, and his leadership will be central to advancing Solvonis' pipeline of novel therapeutics for addiction and mental health disorders."
The company said Nutt will lead the scientific strategy and clinical development of its growing pipeline. This includes SVN-001, a combination of intravenous ketamine and cognitive behavioural therapy for severe alcohol use disorder; SVN-SDN-14, a programme focused on multi-receptor modulation for trauma-related mental health disorders; and SVN-002, an esketamine formulation targeting AUD alongside therapy.
Moreover, he will "oversee scientific direction, asset prioritisation, and translational development across the early-stage pipeline" of patented chemical series in the firm's proprietary CNS compound library.
"It's a privilege to take on this expanded role at Solvonis at such a pivotal stage in the company's growth," Nutt commented. "Solvonis is distinguished by its unwavering commitment to rigorous neuroscience, translational innovation, and clinically grounded development...The pipeline reflects both ambition and focus, with the potential to deliver transformative treatments for brain disorders that continue to impose an immense personal and societal burden.
"I look forward to helping accelerate the development of therapies that are not only scientifically robust, but capable of making a real difference in patients' lives at scale."
Shares in Solvonis were trading 1.9% lower at 0.13 pence in London on Tuesday afternoon.
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Solvonis Therap